Connect with us

News Wire

Glenmark Pharmaceuticals and SaNOtize Announce Peer Reviewed Publication of Its Phase 3 Clinical Trials on SaNOtize’s Novel Nitric Oxide Nasal Spray for COVID-19 in Lancet Journal

–  The Lancet Regional Health Southeast Asia publishes the successful phase 3 clinical trial results of Nitric Oxide Nasal Spray.

–  Phase 3 trial of Nitric Oxide Nasal Spray administered to adult COVID-19 patients in India met the key endpoints and demonstrated reductions of viral load of 94% in 24 hours and 99% in 48 hours.

–  Nitric Oxide Nasal Spray was safe and well tolerated in COVID-19 patients.

–  Following positive results and regional approvals, Glenmark launched this nasal spray in India under the brand name FabiSpray® and in Singapore and Hong Kong under the brand name VirX™.

MUMBAI, India and VANCOUVER, BC, July 13, 2022 /PRNewswire/ — Glenmark Pharmaceuticals Limited (Glenmark), an innovation-driven, global pharmaceutical company, and SaNOtize Research and Development Corp, today announced that The Lancet Regional Health Southeast Asia (TLRHSEA) – peer reviewed, high impact journal published the successful phase 3 clinical trial results of SaNOtize’s Nitric Oxide Nasal Spray (NONS) study titled: ‘SARS-CoV-2 accelerated clearance using a novel nitric oxide nasal spray (NONS) treatment: A randomized trial’.

PRNE_Glenmark_Logo

https://www.thelancet.com/journals/lansea/article/PIIS2772-3682(22)00046-4/fulltext

“We are excited to publish the study of the novel Nitric Oxide Nasal Spray, which positively impacts the lives of people, in The Lancet group of journals. The robust double-blind trial demonstrated significant efficacy and remarkable safety of NONS. This therapy has the potential to make a crucial contribution to COVID-19 management, with its ease of use in the current highly transmissible phase of pandemic,” said Dr. Monika Tandon, Senior VP & Head – Clinical Development, Glenmark Pharmaceuticals Ltd.

The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment. Viral load was reduced by 93.7% within 24 hours and by 99% within 48 hours of treatment with NONS. The average change from baseline in log viral RNA load through the entire treatment duration was statistically superior with NONS compared to placebo. Similar results were observed in vaccinated and unvaccinated populations. The study was conducted during the delta and omicron surges. Key secondary endpoints including clinical improvement assessed by WHO Clinical Progression Scale Score and extent/rapidity of virologic recovery was demonstrated in patients using NONS. The median time to virological cure was three days in the NONS group and seven days in the placebo group after start of treatment (four days sooner). The exploratory evaluation of the proportion of immediate contacts having a positive COVID-19 test or becoming symptomatic, remained nearly the same in the NONS group while it numerically increased in the placebo group over the treatment. 

“The Phase 3 study results strongly support the safety and efficacy of NONS in the treatment of COVID-19 and its known variants,” said Gilly Regev, PhD, SaNOtize Co-Founder and CEO. “Nitric oxide blocks entry into the nasal passage, kills the virus, and stops its replication, which is why viral load is reduced so rapidly with NONS. Viral load has been linked to infectivity, poorer health outcomes, and complications from long COVID. The evidence is mounting that NONS represents an effective, well tolerated antiviral treatment that significantly shortens the course of COVID-19.”

Study Design

The study was conducted by Glenmark in 306 vaccinated and non-vaccinated adults of symptomatic mild COVID-19 across 20 clinical sites in India. This randomized, double-blind phase 3 clinical trial evaluated a seven-day treatment of NONS plus standard of care versus placebo nasal spray plus standard care in patients with symptomatic COVID-19. The primary outcome measure of nasal SARS-CoV-2 RNA accelerated clearance was used to assess the efficacy of this transformational NONS in high-risk patients (unvaccinated, or 45 years of age, or had one or more comorbidities) after seven days of treatment. Exploratory evaluation of NONS in prevention of infection in immediate contacts of these COVID-19 patients was also evaluated.

NONS treatment was found to be well tolerated, establishing an advantage of locally acting nasal therapy. None of the patients reported any moderate or severe adverse events. There were no clinically significant changes from baseline observed in methemoglobin suggesting lack of systemic availability of nitric oxide from nasal spray. Additionally, neither nasal vasodilation symptoms nor systemic vasodilation signs were observed in either treatment.

Strategic Partnership with SaNOtize

In July 2021, Glenmark entered into an exclusive long term strategic partnership with Canadian biotech firm SaNOtize, to manufacture, market and distribute its breakthrough Nitric Oxide Nasal Spray for COVID-19 treatment in India and other Asian markets including Singapore, Malaysia, Hong Kong, Taiwan, Nepal, Brunei, Cambodia, Laos, Myanmar, Sri Lanka, Timor-Leste and Vietnam.

Global Approvals for NONS

Glenmark launched NONS under the brand name FabiSpray® in February 2022, after receiving manufacturing and marketing approval from the Drugs Controller General of India (DCGI) as part of the accelerated approval process. NONS has already received a CE mark in Europe, which is an equivalent of marketing authorization in case of a Medical Device. By virtue of the CE mark, SaNOtize has permission to launch NONS in the EU. NONS is also approved and being sold in Singapore, Hong Kong, Israel, Thailand, Indonesia and Bahrain, under the name enovid™ or VirX™. Outside of India, NONS has also been approved globally for protection against viruses, including SARS COV-2.

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is an innovation-driven global pharmaceutical company with a presence across Specialty, Generics and OTC businesses. It focuses on the key therapeutic areas of respiratory, dermatology and oncology. The company has 10 world-class manufacturing facilities spread across 4 continents and operations in over 80 countries. Glenmark is ranked among the world’s top 100 biopharmaceutical companies (Top 100 Companies Ranked by Pharmaceutical Sales, 2020, by In Vivo/Scrip 100) and among the world’s top 50 companies in the off-patent sector (Top 50 Generics and Biosimilars Companies ranked by Sales, 2020, by Generics Bulletin/In Vivo). The company was listed on the Dow Jones Sustainability Index (DJSI), one of the world’s most respected and widely accepted sustainability benchmarks, under the category of emerging markets (2021) for the fourth consecutive year. For more information, visit www.glenmarkpharma.com.

Follow us on Social Media:

LinkedIn (Glenmark Pharmaceuticals) and Instagram (glenmark_pharma)

About SaNOtize

SaNOtize Research & Development Corp. is a pharmaceutical company based in Vancouver, BC, commercializing the multi-faceted antimicrobial properties of a liquid producing nitric oxide. The company has developed and patented a Nitric Oxide Releasing Solution platform technology (NORS™) to treat and prevent upper respiratory and topical infections. For more information, visit www.SaNOtize.com. Follow us on social: LinkedIn, Twitter.

Logo: https://oyefilmy.com/wp-content/uploads/2022/07/glenmark-pharmaceuticals-and-sanotize-announce-peer-reviewed-publication-of-its-phase-3-clinical-trials-on-sanotizes-novel-nitric-oxide-nasal-spray-for-covid-19-in-lancet-journal-1.jpg

Related Topics:
Continue Reading
Advertisement
Click to comment

You must be logged in to post a comment Login

Leave a Reply

News Wire

Fulfilling PM Modi’s Dream of Atmanirbhar Bharat: India’s AI Writing Startup Kreativespace Incubated at IIT Kharagpur

  1. Kreativespace, an Indian AI-powered writing platform founded by Vinet Kakadea, has been incubated at IIT Kharagpur and recognized by SVNIT University, Ministry of Education under Bodhan AI Conclave also through the NVIDIA Inception Program, AWS Startup Program, and DPIIT under Startup India.
  2. The platform unifies 8 AI-powered writing tools, along with AI Humanizer and Message AI feature being the latest addition into a single ecosystem, so you can generate and refine content all in one place.
  3. The company reports more than 50,000+ signed-up users, 75,000+ anonymous users, and roughly 100,000 monthly website visitors, positioning itself as the only Indian company operating at scale in the global AI writing market.

SURAT, India, June 19, 2026 /PRNewswire/ — Kreativespace, an AI-powered writing platform, is building out its position as the only homegrown alternative in a market long dominated by international tools such as Grammarly and QuillBot. Founded by Vinet Kakadea and incubated at IIT Kharagpur, the company has aligned its growth with the broader push behind Prime Minister Narendra Modi’s Atmanirbhar Bharat (Self-Reliant India) initiative, which encourages indigenous technology development capable of competing on a global scale.

Kreativespace Incubated at IIT Kharagpur

As AI adoption accelerates across India’s education, research, and enterprise sectors, Kreativespace is among a small group of Indian startups building writing technology designed to compete directly with established international platforms.

Kreativespace’s progress has been recognized by several institutions central to India’s startup and technology ecosystem. The company has been incubated at IIT Kharagpur, selected under SSIP 2.0 through SVNIT University, and chosen by the Ministry of Education to present its work at the Bodhan AI Conclave. It has also been accepted into the NVIDIA Inception Program and the AWS Startup Program, and holds DPIIT recognition under the Startup India initiative.

Where many writing-tool users rely on separate subscriptions for content generation to refinement for grammar correction, paraphrasing, plagiarism checking, citation generation, and editing, Kreativespace brings these functions into a single platform as a super-app for AI writing tools. The company says its approach centers on affordability and accessibility alongside performance, aiming to make advanced AI writing assistance available to a wider range of users regardless of geography or budget.

The idea for Kreativespace took shape while founder Vinet Kakadea was studying at New York University and Marymount University in the United States, where he experienced firsthand how students, researchers, and professionals often need multiple paid subscriptions to cover writing-related tasks. That fragmented experience led him to build a super-app offering each of these capabilities together, at a more accessible price point.

Kreativespace combines 8 AI-powered writing tools with AI Humanizer and Message AI feature being the latest addition, allowing users to generate, rewrite, refine, and humanize content without moving between separate platforms. The product is available via web platform, mobile apps on the App Store and Google Play, browser extensions for Chrome, Mozilla, and Edge, and a Google Docs add-on.

Vinet Kakadea, Founder of Kreativespace, said, “Kreativespace’s vision is to digitalize the entire Indian education ecosystem to support PM Modi’s Atmanirbhar Bharat scheme.”

About Kreativespace

Kreativespace with the Motto of Making Writing Accessible for Everyone: Kreativespace is an AI-powered writing platform built to make AI writing tools accessible, affordable, and effective for students, researchers, educators, professionals, content creators, startups, and enterprises. Founded by Vinet Kakadea, the company is incubated at IIT Kharagpur and has been recognized by AWS Startup Program, the NVIDIA Inception Program, and DPIIT under Startup India. For more information, visit kreativespace.com.

Cision View original content to download multimedia:https://www.prnewswire.com/in/news-releases/fulfilling-pm-modis-dream-of-atmanirbhar-bharat-indias-ai-writing-startup-kreativespace-incubated-at-iit-kharagpur-302804117.html

Continue Reading

News Wire

Santokbaa Humanitarian Award 2026 Marks 20 Years of Compassion and Service

SURAT, India, June 18, 2026 /PRNewswire/ — The Santokbaa Humanitarian Award 2026, instituted by Shree Ramkrishna Knowledge Foundation (SRKKF), the philanthropic arm of Shree Ramkrishna Exports (SRK), marked 20 years of honouring individuals who have made a lasting difference through compassion, service and leadership. The awards were presented recently in Surat.

This year’s Santokbaa Humanitarian Award was conferred on Padma Shri Dr. Gullapalli N. Rao, renowned Indian ophthalmologist and Founder-Chair of the LV Prasad Eye Institute, and Padma Shri Smt. Reema Nanavaty, development worker and Director of the Self-Employed Women’s Association (SEWA). Their work has touched millions of lives through healthcare, empowerment and community development.

In a significant addition this year, SRKKF introduced the Social Entrepreneur Award to recognise leaders who combine business excellence with measurable social impact. The inaugural award was presented to Shri Srikanth Bolla, Founder of Bollant Industries, a sustainable manufacturing company known for disability-inclusive employment and environmentally responsible practices.

The event was graced by Chief Guest Shri Harivansh Narayan Singh, Hon’ble Deputy Chairman of the Rajya Sabha and Guests of Honour Shri Harsh Sanghavi, Hon’ble Deputy Chief Minister of Gujarat; along with several other distinguished personalities.

Established in 2006 by Shri Govind Dholakia, Founder & Chairman Emeritus of Shree Ramkrishna Exports Pvt. Ltd. and SRKKF, the award reflects the legacy of compassion and selfless values embodied by his mother, Santokbaa. Over the past two decades, it has become a platform to honour individuals whose lives and work continue to inspire society.

The awardees are selected through a rigorous and transparent process led by an independent jury comprising leaders from diverse fields. The 2026 jury included Shri Govindan Rangarajan, Director, Indian Institute of Science (IISc), Bengaluru; Shri A.S. Kiran Kumar, Former Chairman, ISRO; Admiral R. Hari Kumar (Retd.), Former Chief of the Indian Navy; Shri Rishabh Shroff, Partner, Cyril Amarchand Mangaldas; and Shri Shreyans Dholakia, Entrepreneur and Brand Custodian, SRK.

Addressing the gathering, Chief Guest Shri Harivansh Narayan Singh said that the SRK Foundation is carrying forward Santokbaa’s legacy to the next generation by celebrating service, sacrifice and compassion over wealth or fame. He added that the family’s effort to connect this legacy with social entrepreneurship reflects the values of nation-building.

Shri Harsh Sanghavi said the Santokbaa Award reminds us that true achievement lies not only in personal success, but in bringing light and happiness to others. Shri Govind Dholakia said his mother Santokbaa spent her life guided by truth, love and compassion, and that her values continue to inspire the family’s work. He added that the award’s 20-year journey is a tribute to changemakers whose efforts have strengthened communities across the country.

Speaking on the honour, Dr. Gullapalli N. Rao said it was a privilege to receive the recognition on behalf of all those working to expand access to quality eye care. He said restoring sight restores dignity and opportunity, and praised SRK’s world-class operational systems. Smt. Reema Nanavaty said the award belonged to the millions of women whose resilience and entrepreneurial spirit continue to inspire SEWA’s mission. She noted that when women are empowered, they become agents of change for their families and communities. Shri Srikanth Bolla said his journey has shown that limitations often exist more in perception than reality, and that the award is a reminder that with the right support, every individual can contribute meaningfully to society.

Over the past 20 years, the Santokbaa Humanitarian Award has honoured 20 of India’s most distinguished humanitarian and social leaders, including Shri Ratan Tata, His Holiness the 14th Dalai Lama, Dr. Sudha Murty, Dr. Cyrus Poonawalla, Shri Shiv Nadar, Dr. Abhay Bang and Dr. Rani Bang, Dr. Verghese Kurien, Shri Kailash Satyarthi and Shri A.S. Kiran Kumar. With the introduction of the Social Entrepreneurship Award in 2026, the milestone celebration reaffirmed the importance of empathy, service and purposeful leadership in building a better future.

About Santokbaa Humanitarian Award:

Over the past 20 years, the Santokbaa Humanitarian Award has honoured 19 of India’s most distinguished humanitarian and social leaders, including Shri Ratan Tata, His Holiness the 14th Dalai Lama, Dr. Sudha Murty, Dr. Cyrus Poonawalla, Shri Shiv Nadar, Dr. Abhay Bang and Dr. Rani Bang, Dr. Verghese Kurien, Shri Kailash Satyarthi and Shri A.S. Kiran Kumar, among other eminent personalities. In 2026, SRKKF also instituted the Santokbaa Social Entrepreneurship Award, with Shri Srikanth Bolla becoming its inaugural recipient.

As the Santokbaa Humanitarian Award completed a remarkable 20-year journey, the milestone celebration reaffirmed the enduring importance of empathy, service and purposeful leadership in shaping a better future. The journey endures, contributing to nation-building through compassion, innovation and service to humanity.

For more information, visit: https://srk.foundation/honours

Photo: https://oyefilmy.com/wp-content/uploads/2026/06/santokbaa-humanitarian-award-2026-marks-20-years-of-compassion-and-service-1.jpg

 

Cision View original content to download multimedia:https://www.prnewswire.com/in/news-releases/santokbaa-humanitarian-award-2026-marks-20-years-of-compassion-and-service-302804299.html

Continue Reading

News Wire

Osstem Implant Accelerates Innovation in India with ‘Denall TV’, a Digital Dental Education Hub

  • Over the past two years since its launch in April 2024, Denall TV has become a core platform for digital dental education in India.
  • Opened a dedicated Denall Studio in India in July 2025, strengthening live hands-on and professional training programs.
  • Supporting the professional growth of clinicians through practical content, including ‘Master Courses’ and ‘Product Reviews’.

NEW DELHI and MUMBAI, India, June 15, 2026 /PRNewswire/ — Osstem Implant announced that its specialized dental education platform for the Indian market, ‘Denall TV’ (https://in.denall.com), is gaining significant traction among local practitioners, establishing itself as a vital hub for digital dental education in India.

The thumbnail for the ‘Implant System Introduction’ lecture, the most-watched content on Denall TV India
  •  Building a Comprehensive Digital Clinical Education Environment

Since launching its first content in April 2024, Denall TV has continuously evolved to meet the needs of Indian clinicians. To provide more immersive and high-quality education, Osstem Implant established a dedicated Denall Studio in India in July 2025. This facility has enabled the creation of a systematic digital clinical education environment, overcoming geographical limitations for dentists across the country.

  • Providing High-Quality, Practice-Oriented Clinical Content

The platform focuses on promoting ‘Digital Dentistry’ through specialized ‘Digital Surgery’ education and providing accurate product information. Denall TV consistently uploads essential clinical content, including: Live Hands-on sessions, Practical Master Courses, Expert product reviews featuring items such as the T2 Plus and 122 Taper KIT, helping clinicians make informed decisions for their practices.

  • Strengthening Trust as a Strategic Education Partner

Professional clinical courses have become a major topic of interest among local medical professionals. Notably, the ‘Implant System Introduction’ lecture has surpassed 25,000 views, proving the platform’s high influence. This achievement signifies that Osstem Implant has successfully established itself as a trusted education partner in the Indian market, going beyond its role as a manufacturer.

  • Bridging Global Trends and Improving Educational Accessibility

Osstem Implant connects local practitioners with global academic networks. The platform provides timely content from global academic events such as the ‘2026 Osstem World Meeting in Bangkok’, sharing the latest implant trends and technological advancements with the Indian dental community. By offering online access, Denall TV effectively bridges the educational gap for dentists in regions where offline seminars are difficult to attend.

An official from Osstem Implant India stated, “Denall TV serves as a key bridge, delivering world-class clinical knowledge to local dentists. We will continue to strengthen our real-time interactive webinars to provide deeper clinical insights.” The official added, “We are committed to driving both the quantitative and qualitative growth of the Indian dental implant market through the continued provision of high-quality educational content.”

Moving forward, Osstem Implant plans to enhance its B2C PR strategies centered around the Denall TV platform and lead the popularization of digital dental treatment in India through close communication with local practitioners.

Photo – https://oyefilmy.com/wp-content/uploads/2026/06/osstem-implant-accelerates-innovation-in-india-with-denall-tv-a-digital-dental-education-hub-1.jpg

Cision View original content:https://www.prnewswire.com/in/news-releases/osstem-implant-accelerates-innovation-in-india-with-denall-tv-a-digital-dental-education-hub-302796515.html

Continue Reading

Trending